At 7.9% CAGR, the Europe Lung Cancer Screening market is projected to be worth US$ 1,090.99 million by 2030, says Business Market Insights

According to Business Market Insights research, the Europe lung cancer screening market was valued at US$ 593.25 million in 2022 and is expected to reach US$ 1,090.99 million by 2030, registering a CAGR of 7.9% from 2022 to 2030. Rising lung cancer incidences and increasing government are the critical factors attributed to the Europe lung cancer screening market.

Several countries face challenges with lung cancer screening programs. On behalf of the Ministry of Health, the RIVM Center for Population Screening (RIVM-CvB) leads and manages the National Population Screening Programme; under which all Dutch citizens are invited, at a certain point in their lives, to participate in one of the national screening programs. The State begins, sets up, and finances three cancer population screening programs.

Therefore, there is a crucial requirement for a well-structured program such as a community-based program or a shared, informed decision-making program between clinicians and potential participants; accredited reporting centers; and a central data registry for quality control, monitoring, and outcome reporting. Additionally, integrated smoking cessation intervention, international data supporting cost-effectiveness, additional mortality benefits, and a high sustainability rate are a few factors that must be studied for lung cancer screening. Therefore, the implementation of structured lung cancer screening programs is expected to be a lucrative opportunity in the Europe Lung Cancer Screening Market during the forecast period.

On the contrary, high cost of lung cancer screening hampers the Europe lung cancer screening market.  

Based on cancer type, the Europe lung cancer screening market is segmented into non–small cell lung cancer (NSCLC) and small cell lung cancer. The non–small cell lung cancer (NSCLC) segment held 79.7% share of Europe lung cancer screening market in 2022, amassing US$ 472.65 million. It is projected to garner US$ 855.61 million by 2030 to expand at 7.7% CAGR during 2022–2030.

Based on technology, the Europe lung cancer screening market is segmented into chest X-ray, low dose computed tomography (LDCT), liquid biopsy, and others. The low dose computed tomography (LDCT) segment held 44.6% share of Europe lung cancer screening market in 2022, amassing US$ 264.69 million. It is projected to garner US$ 501.92 million by 2030 to expand at 8.3% CAGR during 2022–2030.

Based on age group, the Europe lung cancer screening market is segmented into 50 and older and below 50. The 50 and older segment held 89.3% share of Europe lung cancer screening market in 2022, amassing US$ 529.64 million. It is projected to garner US$ 967.31 million by 2030 to expand at 7.8% CAGR during 2022–2030.

Based on end user, the Europe lung cancer screening market is segmented into hospitals, diagnostic centers, and others. The hospitals segment held 43.4% share of Europe lung cancer screening market in 2022, amassing US$ 257.55 million. It is projected to garner US$ 456.06 million by 2030 to expand at 7.4% CAGR during 2022–2030.

Based on country, the Europe lung cancer screening market has been categorized into the Germany, the UK, France, Italy, Spain, and the Rest of Europe. Our regional analysis states that Germany captured 25.6% share of Europe lung cancer screening market in 2022. It was assessed at US$ 151.93 million in 2022 and is likely to hit US$ 275.37 million by 2030, exhibiting a CAGR of 7.7% during the forecast period.      

Key players operating in the Europe Lung Cancer Screening market are Intelerad Medical Systems, Nuance Communications Inc, GE HealthCare, Medtronic, Canon Inc, Koninklijke Philips NV, Siemens AG, and bioAffinity Technologies, Inc among others.  

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com